Graypoint LLC Has $870,000 Stake in Zoetis Inc. (NYSE:ZTS)

Graypoint LLC decreased its position in Zoetis Inc. (NYSE:ZTS) by 12.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,338 shares of the company’s stock after selling 760 shares during the quarter. Graypoint LLC’s holdings in Zoetis were worth $870,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp raised its stake in shares of Zoetis by 0.5% in the 3rd quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the period. Geode Capital Management LLC raised its stake in shares of Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after purchasing an additional 185,364 shares during the period. Mizuho Securities USA LLC raised its stake in shares of Zoetis by 13,726.9% in the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after purchasing an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Zoetis by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after purchasing an additional 194,542 shares during the period. Finally, Clearbridge Investments LLC raised its stake in shares of Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after purchasing an additional 166,517 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Zoetis stock opened at $163.30 on Friday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The stock’s 50 day moving average is $171.71 and its 200-day moving average is $180.14. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $73.68 billion, a price-to-earnings ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the business earned $1.36 earnings per share. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts expect that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.22%. This is an increase from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ZTS shares. Leerink Partners started coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.